38.64 USD
-0.35 (-0.9%)
38.64 USD
0 (0%)
Overall RPRX gets a fundamental rating of 6 out of 10. We evaluated RPRX against 191 industry peers in the Pharmaceuticals industry. While RPRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.
1. Profitability
1.1 Basic Checks
RPRX had positive earnings in the past year.
RPRX had a positive operating cash flow in the past year.
RPRX had positive earnings in each of the past 5 years.
RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RPRX has a Return On Assets of 3.95%. This is amongst the best in the industry. RPRX outperforms 84.82% of its industry peers.
Looking at the Return On Equity, with a value of 11.93%, RPRX belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
RPRX has a better Return On Invested Capital (6.43%) than 84.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RPRX is significantly below the industry average of 12.85%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
RPRX has a better Profit Margin (32.55%) than 95.29% of its industry peers.
In the last couple of years the Profit Margin of RPRX has declined.
With an excellent Operating Margin value of 65.22%, RPRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RPRX has less shares outstanding
The number of shares outstanding for RPRX has been increased compared to 5 years ago.
The debt/assets ratio for RPRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.67, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
RPRX has a Altman-Z score (1.67) which is in line with its industry peers.
The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.47, RPRX is in the better half of the industry, outperforming 79.06% of the companies in the same industry.
RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 76.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.67 |
ROIC/WACC0.75
WACC8.55%
2.3 Liquidity
A Current Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
RPRX has a Current ratio (3.48) which is in line with its industry peers.
RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.48, RPRX perfoms like the industry average, outperforming 57.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.24% over the past year.
The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
The Revenue has been growing slightly by 3.70% in the past year.
RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.52% yearly.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.58% yearly.
The Revenue is expected to grow by 10.36% on average over the next years. This is quite good.
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y12.58%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.40, the valuation of RPRX can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 91.62% of the companies listed in the same industry.
RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.51.
Based on the Price/Forward Earnings ratio of 7.46, the valuation of RPRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
RPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 7.46 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, RPRX is valued cheaply inside the industry as 82.72% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.61 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RPRX may justify a higher PE ratio.
A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.24%.
Compared to an average industry Dividend Yield of 0.61, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.19% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.24% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
38.64
-0.35 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.29%
Inst Owner Change-2.73%
Ins Owners1.82%
Ins Owner Change7.69%
Market Cap22.30B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts82.67
Price Target46.34 (19.93%)
Short Float %7.15%
Short Ratio6.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.24% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0.74%
PT rev (3m)4.97%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)2.19%
EPS NY rev (1m)4.96%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)1.1%
Revenue NY rev (3m)1.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 7.46 | ||
| P/S | 9.49 | ||
| P/FCF | 23.61 | ||
| P/OCF | 9.27 | ||
| P/B | 3.48 | ||
| P/tB | 4.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.64%
EPS(NY)5.18
Fwd EY13.4%
FCF(TTM)1.64
FCFY4.24%
OCF(TTM)4.17
OCFY10.78%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.54
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.67 |
F-Score5
WACC8.55%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y12.58%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.36%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.71%
EBIT Next 3Y14.53%
EBIT Next 5Y13.57%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.4 and the Price/Book (PB) ratio is 3.48.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.